Meeting
2017 Gastrointestinal Cancers Symposium
Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers.
Authors
Amy E. Chang
University of Washington, Seattle, WA
Amy E. Chang , Safi Shahda , William Proctor Harris , Stacey Cohen , Andrew L. Coveler , Bert H. O'Neil , Vijayakrishna K. Gadi , Reina Hibbert , Hannah H Lee , Anne Younger , Kinsey Ann McCormick , Colin Pritchard , Mary Weber Redman , E. Gabriela Chiorean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02451553
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS515)
DOI
10.1200/JCO.2017.35.4_suppl.TPS515
Abstract #
TPS515
Poster Bd #
O11
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
First Author: Andrea Wang-Gillam
Poster
2013 ASCO Annual Meeting
A phase I study of the BCR-ABL tyrosine kinase inhibitor nilotinib and cetuximab in patients with solid tumors that can be treated with cetuximab.
First Author: Brandon George Smaglo
Poster
2012 ASCO Annual Meeting
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
First Author: Jean-Luc Van Laethem
Poster
2011 ASCO Annual Meeting
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
First Author: R. Dienstmann